Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine)
(firmenpresse) - MONTREAL, CANADA -- (Marketwire) -- 12/12/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today the Canadian launch of DigiFab™ Digoxin Immune Fab (Ovine). DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.
Digoxin (also known as digitalis) is a drug used to treat heart failure and to slow the rate in some cardiac conditions. There are approximately 1.6 million digoxin prescriptions written annually in Canada. Digoxin is known to have a narrow therapeutic window and patients can easily move from a therapeutic to toxic dose through excessive dosing, slow elimination and metabolism or through interactions with other drugs. Digoxin toxicity can cause potentially life-threatening heart rhythm disturbances.
Paladin acquired the exclusive Canadian rights to market and sell DigiFab™ from BTG International Inc., in February 2010.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at .
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2010. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at .
Contacts:
Samira Sakhia, CA, MBA
Chief Financial Officer
Paladin Labs Inc.
514-669-5367
514-344-4675 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 1064856
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONTREAL, CANADA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 114 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine)
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paladin Labs Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
